ARTICLE | Finance

Regulatory milestones

Highlights of weekly biotech stock moves

December 6, 2010 8:00 AM UTC

Regulatory, clinical and other news for the two weeks ending Dec. 3.

Acrux Ltd. (ASX:ACR) gained A$0.27 to A$3.33 Thanksgiving week after FDA approved an NDA for Axiron testosterone as replacement therapy in men for conditions associated with a deficiency or absence of testosterone, including primary and hypogonadotropic hypogonadism. Eli Lilly and Co. (NYSE:LLY), which has worldwide rights, plans to launch the testosterone metered-dose lotion in mid-2011...